FDA Approves Bristol Myers' Opdivo Plus Chemo In Neoadjuvant Lung Cancer Setting

Loading...
Loading...

The FDA has approved Bristol Myers Squibb Co's BMY Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting.

  • The agency approved the Opdivo combo just five days after accepting the application.
  • The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer.
  • Opdivo-based combinations are now approved in metastatic and earlier non-small cell lung cancer stages.
  • Opdivo plus chemotherapy is approved regardless of PD-L1 status.
  • The approval is based on the CheckMate -816 trial. Opdivo plus chemo showed a statistically significant improvement in event-free survival with a 37% reduction in the risk of progression, recurrence, or death compared to chemotherapy alone.
  • Opdivo plus chemotherapy showed a median EFS of 31.6 months compared to 20.8 months for patients treated with chemotherapy alone.
  • Additionally, 24% of patients treated with Opdivo plus chemotherapy achieved pCR, compared to 2.2% of patients treated with chemotherapy alone.
  • Price Action: BMY shares closed 0.14% lower at $69.25 during after-hours trading on Friday.
Posted In: BiotechNewsHealth CareFDAGeneralBriefsNon-Small Cell Lung Cancer
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...